Drug shortage risk for Endo Pharmaceuticals after factory shut down

Endo Pharmaceuticals (NASDAQ:ENDP) faces a drug shortage risk for some of its opiates, such as Percocet, as Novartis Consumer Group sorts out a mix-up that could cause extended release opiates for Endo Pharmaceuticals to be bottled together with over-the-counter pain reliever Excedrin and stimulant NoDoz.The factory shutdown, though temporary, could cause a shortage for Endo’s [...]

[Read more of this report]


N.C. Novartis site is first cell-based flu vaccine facility in the country

If a flu pandemic strikes the United States, a Novartis (NYSE:NVS) plant in North Carolina now stands ready to respond with vaccine techniques that offer speed and scalability advantages over traditional vaccine-making methods.Novartis’ vaccine facility in Holly Springs, North Carolina today became the first cell culture vaccine facility authorized by the U.S. Food and Drug [...]

[Read more of this report]


Novartis gets FDA warning letter for N.C., Colorado and Quebec plants

The U.S. Food and Drug Administration is taking Novartis (NYSE:NVS) CEO Joseph Jimenez to task with a warning letter that cites three of the company’s manufacturing facilities for “significant violations” at the company’s generics drug unit Sandoz.The warning letter, sent to Jimenez on Nov. 18, outlines a long list of findings including insufficient written procedures [...]

[Read more of this report]


Watson gets approval for morphine drug, but faces Novartis legal challenge

Watson Pharmaceuticals (NYSE:WPI) got approval from the U.S. Food and Drug Administration for its abbreviated new drug application for morphine sulfate extended-release capsules, the generic version of Actavis‘ Kadian, according to a statement from the company.The drug manages moderate to severe prolonged pain. For the year ending Sept. 30, Kadian had about $275 million in [...]

[Read more of this report]


Novartis vaccines executive discusses ‘Contagion’ and the real risks of viruses

The movie “Contagion” is fiction, but ask Novartis (NYSE:NVS) executive Russell Thirsk and he’ll tell you the threats it depicts are quite real.For those who don’t know, “Contagion” tells the story of the worldwide spread of a virulent virus that goes on to kill millions. Thirsk is site head of Novartis’ new vaccine facility in [...]

[Read more of this report]


FDA approves new Novartis drug for rare type of pancreatic cancer (Morning Read)

Among today’s current medical news: Novartis wins FDA approval on a new pancreatic cancer drug; Vermont on its way to introducing single payer health care system; one nurses strike in California starts while another in Massachusetts is averted; and sex, coffee and six other things that can kill you, according to a new study.

[Read more of this report]


Duke vaccine institute to partner with Novartis on pandemic vaccines

Duke University’s Human Vaccine Institute will work with Novartis (NYSE:NVS) to rapidly develop a vaccine in case of a pandemic virus, according to a new five-year agreement.The team of Duke and Novartis investigators will have access to resources at both Duke University and Novartis’ vaccine manufacturing facility in Holly Springs, North Carolina. The facilities are [...]

[Read more of this report]


Cancer expert and former FDA leader von Eschenbach named to Viamet board

Dr. Andrew von Eschenbach, a former U.S. Food and Drug Administration commissioner and a prostate cancer expert, has been elected to the board of directors of Viamet Pharmaceuticals as the Durham, North Carolina-based company looks to advance its technology into clinical testing.

[Read more of this report]


Dell buy puts medical images in the cloud (Morning Read)

Dell said it will acquire Insite One, a developer of applications that enables doctors to share medical images in the cloud, for an undisclosed price, reports VentureBeat.

[Read more of this report]


Novartis finally lands Alcon… for $168 a share

Alcon Inc. (NYSE:ACL) is about to become part of Novartis AG (NYSE:NVS) after the companies’ boards agreed to a merger deal.Basel, Switzerland-based Novartis agreed to pay $168 per ACL share through a combination of its own shares and “a contingent value cash component,” according to a prepared statement from Alcon.That’s a 2.4 percent [...]

[Read more of this report]


Older Posts »

Be a Thought Leader: Join MedCitizens

Anyone can blog on MedCity News when they become a "MedCitizen." MedCitizens publish their own thoughts about current medical news and the latest issues in healthcare to the entire MedCity News audience.

Click to login or learn more

MedCity Twitter Buzz

MedCity Jobs Board

Real Time Web Analytics